National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Liraglutide (Saxenda®), indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial body mass index (BMI) of ≥30kg/m2 (obese), or ≥27kg/m2 to <30kg/m2 (overweight) in the presence of at least one weight-related comorbidity such as dysglycaemia (pre-diabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia or obstructive sleep apnoea.

 

NCPE Assessment Process Complete
Rapid review commissioned 18/09/2019
Rapid review completed 24/10/2019
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of liraglutide (Saxenda®) compared with the current standard of care.